Format

Send to

Choose Destination
Curr Opin Immunol. 2006 Apr;18(2):201-5. Epub 2006 Feb 7.

Therapeutic cancer vaccines.

Author information

1
Center for Immunotherapy of Cancer and Infectious Diseases, Department of Immunology, University of Connecticut School of Medicine, Farmington, CT 06030-1601, USA. srivastava@nso2.uchc.edu

Abstract

The immunological bases of current approaches to therapeutic cancer vaccination (or 'vacci-treatment') have been established for a decade or longer. The new developments lie mostly in the lessons learnt from clinical testing of these approaches. Three lessons are particularly worthy of note. First, recently completed randomized Phase 3 trials suggest that vacci-treatment with autologous dendritic cells expressing prostatic acid phosphatase (for prostate cancer) or with autologous tumor-derived heat shock protein (gp96)-peptide complexes show promise in enhancing survival of cancer patients. These two approaches are undergoing further randomized clinical testing. Second, immunological monitoring of many clinical trials has failed to identify a surrogate marker for clinical outcomes. Finally, an increasing volume of literature suggests that protective immunity to human cancers is elicited by the mutated antigenic repertoire unique to each cancer.

PMID:
16464565
DOI:
10.1016/j.coi.2006.01.009
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center